https://scholars.lib.ntu.edu.tw/handle/123456789/495125
標題: | MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib | 作者: | Bean J. Brennan C. JIN-YUAN SHIH Riely G. Viale A. Wang L. Chitale D. Motoi N. Szoke J. Broderick S. Balak M. Chang W.-C. CHONG-JEN YU Gazdar A. Pass H. Rusch V. Gerald W. Huang S.-F. PAN-CHYR YANG Miller V. Ladanyi M. CHIH-HSIN YANG Pao W. |
公開日期: | 2007 | 卷: | 104 | 期: | 52 | 起(迄)頁: | 20932-20937 | 來源出版物: | Proceedings of the National Academy of Sciences of the United States of America | 摘要: | In human lung adenocarcinomas harboring EGFR mutations, a second-site point mutation that substitutes methionine for threonine at position 790 (T790M) is associated with approximately half of cases of acquired resistance to the EGFR kinase inhibitors, gefitinib and erlotinib. To identify other potential mechanisms that contribute to disease progression, we used array-based comparative genomic hybridization (aCGH) to compare genomic profiles of EGFR mutant tumors from untreated patients with those from patients with acquired resistance. Among three loci demonstrating recurrent copy number alterations (CNAs) specific to the acquired resistance set, one contained the MET proto-oncogene. Collectively, analysis of tumor samples from multiple independent patient cohorts revealed that MET was amplified in tumors from 9 of 43 (21%) patients with acquired resistance but in only two tumors from 62 untreated patients (3%) (P = 0.007, Fisher's Exact test). Among 10 resistant tumors from the nine patients with MET amplification, 4 also harbored the EGFRT790M mutation. We also found that an existing EGFR mutant lung adenocarcinoma cell line, NCI-H820, harbors MET amplification in addition to a drug-sensitive EGFR mutation and the T790M change. Growth inhibition studies demonstrate that these cells are resistant to both erlotinib and an irreversible EGFR inhibitor (CL-387,785) but sensitive to a multikinase inhibitor (XL880) with potent activity against MET. Taken together, these data suggest that MET amplification occurs independently of EGFRT790M mutations and that MET may be a clinically relevant therapeutic target for some patients with acquired resistance to gefitinib or erlotinib. ? 2007 by The National Academy of Sciences of the USA. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-38049150665&doi=10.1073%2fpnas.0710370104&partnerID=40&md5=5d4b6e7df283898db87508ac9596fb60 https://scholars.lib.ntu.edu.tw/handle/123456789/495125 |
ISSN: | 0027-8424 | DOI: | 10.1073/pnas.0710370104 | SDG/關鍵字: | cl 387785; epidermal growth factor receptor; epidermal growth factor receptor kinase inhibitor; erlotinib; gefitinib; phosphotransferase inhibitor; unclassified drug; xl 880; amino acid substitution; article; cancer resistance; comparative genomic hybridization; controlled study; gene amplification; gene locus; gene mutation; growth inhibition; human; human cell; human tissue; lung adenocarcinoma; point mutation; priority journal; proto oncogene; Adenocarcinoma; Antineoplastic Agents; Chromosomes, Human, Pair 7; Cohort Studies; DNA Mutational Analysis; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, Epidermal Growth Factor |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。